NAS:UTHR (USA) Also Trade In: Germany
United Therapeutics Corp $ 105.69 -0.98 (-0.92%)
Warning! GuruFocus has detected 2 Severe warning signs with UTHR. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for UTHR (United Therapeutics Corp) from 1999 to Sep 18 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. United Therapeutics stock (UTHR) PE ratio as of Sep 18 2020 is 10.84. More Details
United Therapeutics PE Ratio (TTM) Historical Data
View and export this data going back to 1999. Start your Free Trial
United Therapeutics PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:IOVA NAS:ADPT NAS:XLRN NAS:RETA NAS:MYOK NAS:ZLAB NAS:FTSV NAS:MRTX NAS:RARE NAS:JAZZ OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address 1040 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for pulmonary arterial hypertension largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Nearly all of its sales are generated within the United States. United also markets a pediatric oncology drug, but its focus largely remains in pulmonary hypertension.